Summary. Short-and long-term regulation of hepatic carbohydrate metabolism by insulin-like growth factor II was studied in primary cultures of adult rat hepatocytes and compared to the metabolic potency of insulin. Insulin-like growth factor II stimulated glycogen synthesis from [14C]glucose, uptake of [3H]aminoisobutyric acid and p4C]lactate formation from pC]glucose up to three-fold. Basal glycogenolysis was inhibited to about 10%, and glucagon-activated glycogenolysis was blocked completely. The enzymatic activity of glucokinase and pyruvate kinase was induced two-fold, the glucagon-dependent induction of phosphoenolpyruvate carboxykinase was antagonized. Compared to insulin, half-maximal responses required up to 50 times higher insulin-like growth factor II concentrations ranging from 10-20 nmol/1. A similar difference was observed for binding affinity of insulin-like growth factor II to the insulin receptor. The interaction with the insulin-like growth factor II/mannose 6-phosphate (IGF-II/Man-6-P) receptor was examined by studying 125I-insulin-like growth factor II binding and uptake of lysosomal enzymes. The affinity of insulin-like growth factor II to the IGF-II/Man-6-P receptor was considerably higher than for the insulin receptor. Antibodies against the IGF-II/Man-6-P receptor did not affect metabolic responses to insulin-like growth factor II, while binding to its receptor and the receptor-mediated endocytosis of arylsulphatase A were strongly inhibited. Thus, in adult rat liver insulin-like growth factor II appeared to exert metabolic actions not via interaction with its own receptor but through low affinity binding to hepatic insulin receptors.
Insulin-like growth factor II (IGF-II) is a polypeptide hormone with structural homologies to insulin and to insulinlike growth factor I (IGF-I) [1, 2] . Whereas several biological functions have been ascribed to these latter hormones, the physiological role of IGF-II, especially in humans, is not understood. In the rat, IGF-II may contribute to the development of embryonic tissues, particularly those of mesodermal origin, while post-natally, plasma levels of IGF-II decrease and tissue IGF-II m-RNA expression is apparently switched off [3, 4] . Recently, direct evidence for a physiological role of IGF-II in rodent embryonic growth was provided by studies where the IGF-II gene was disrupted by gene targetting [5] .
Acute metabolic actions of IGF-II, e. g. hypoglycaemia and stimulation of glycogen synthesis, have been demonstrated in vivo and in vitro, resembling rapid metabolic effects of insulin [6, 7] . IGF-II was shown to bind with high affinity to its putative receptor, a plasma membrane protein with an apparent molecular weight of about 300 kilodaltons (kDa). However, since IGF-II can bind with lower affinity to receptors for insulin and IGF-I, proliferative and metabolic responses were believed not to depend solely on interaction of IGF-II with its own receptor [8] [9] [10] . This latter receptor is identical to the cation-independent mannose 6-phosphate (Man-6-P) receptor that mediates (1) Man-6-P-dependent transport of newly synthesized lysosomal enzymes from the Golgi apparatus to pre-lysosomes and (2) endocytosis of Man-6-P-containing ligands [11, 12] . In contrast to insulin and IGF-I receptors the IGF-II/Man-6-P receptor lacks an intrinsic tyrosine kinase activity [13] . Some reports suggested that biological responses to IGF-II occur via the IGF-II/Man-6-P receptor including stimulatory actions on glycogen synthesis in a human hepatoma (HEP-G2) cell line [13] , amino acid uptake in cultured human myoblasts [14] , Ca 2+ influx in competent Balb/c 3T3 cells [15] , inositol triphosphate formation in basolateral membranes of proximal tubular kidney cells [16] and DNA synthesis in a human erythroleukaemia cell line [17] . A recent report of IGF-II-stimulated coupling of the human IGF-II/Man-6-P receptor to a G~2-protein may provide a mechanism for signal transduction [18] . In contrast, several other studies have led to the conclusion that cellular IGF-II responses may be mediated through either the insulin or IGF-I receptor [8, [19] [20] [21] [22] . In the present work the role of the IGF-II/Man-6-P receptor for short-and long-term metabolic responses to IGF-II was studied in cultured hepatocytes isolated from adult rats, that express the insulin and the IGF-II/Man-6-P receptor, while the IGF-I receptor is virtually absent [23] . 217 monolayers five times with ice-cold phosphate-buffered saline pH7.4 (140 mmol/1 NaC1, 2.6 mmol/1 KC1, 8 mmol/1 Na2HPO4, 1.5 mmol/1 KH2PO4). Aliquots of the medium were analysed for trichloroacetic acid (TCA)-soluble and -insoluble radioactivity to correct for ligand degradation. Cells were solubilized in 0.1% sodium dodecyl sulphate (SDS) and precipitated with TCA to correct for cell-associated degraded label [27] . Binding of 125I-insulin was corrected for unspecific binding (15-20% of total bound radioactivity) determined in the presence of 10 gmol/l unlabelled insulin. Non-specific binding of IGF-II was below 15% of cell-associated ligand.
Materials and methods

Materials
Chemicals were reagent grade and from commercial sources. Human recombinant IGF-II was a gift from Ciba-Geigy AG (Basel, Switzerland); porcine insulin, dexamethasone and Man-6-P (sodium salt) were obtained from Sigma Chemical Co. (Deisenhofen, FRG) (-2000 Ci/mmol) were purchased from Amersham Buchler (Braunschweig, FRG). IGF-II was iodinated by the chloramine T procedure to a specific activity of 500-700 Ci/mmol. Arylsulphatase A antiserum was raised by immunizing a goat with purified human placental arylsulphatase A [24] . The antiserum directed against the IGF-II/Man-6-P receptor purified from human liver was obtained after immunization of a goat as described previously [25] . Formaldehyde-fixed Staphylococcus aureus cell wall preparation (Pansorbin) was from Calbiochem (La Jolla, Calif., USA).
Irnmunoprecipitation of IGF-II/Man-6-P receptor and cross-linking of l25I-IGF-H to hepatocytes
After 32 h of culture, hepatocytes were labelled for 16 h with [35S]methionine (20 gCi/dish). Cells were solubilized in 10 mmol/1 Tris/HC1 buffer pH 7.5 containing 0.5 tool/1 NaC1, 1.5% (w/v) Triton x 100, 0.1% SDS, 1% sodium deoxycholate, 1% (w/v) BSA, 1 mmol/1 EDTA, 1 mmol/1 phenylmethylsulphonyl fluoride and 5 mmol/1 iodoacete amide. The labelled IGF-II/Man-6-P receptor were immunoprecipitated by the aid of Pansorbin, solubilized and analysed by SDS/polyacrylamide (5%) gel electrophoresis (PAGE) and fluorography as described previously [28] . Cell surface IGF-II/Man-6-P receptors were cross-linked to ~25I-IGF-II as reported [29] . Briefly, 32 h pre-cultured hepatocytes were incubated for 16 h at 4~ with 125I-IGF-II (106 cpm/dish) in 0.1 mol/1 HEPES buffer pH7.6 containing 0.12mol/1 NaC1, 5mmol/1 KC1, 1.2mmol/1 MgSO4, 8 mmol/1 glucose and 0.1% (w/v) BSA. After washing in BSA-free buffer cross-linking was carried out with 0.5 mmol/1 disuecinimidyl suberate. After 15 min the reaction was stopped by 0.15 tool/1 Tris/HC1 pH 7.4 containing 1.5 mmol/l EDTA. Cells were solubilized and analysed under reducing conditions by SDS/PAGE (5% polyacrylamide). Dried gels were autoradiographed using Hyperfilm MP (Amersham Buchler) and Lightning Plus intensifier screens (Du Pont). Alternatively, the IGF-II/Man-6-P receptor was cross-linked to ~2sI-IGF-II and immunoprecipitated from solubilized cells as described above.
Cell culture
Hepatocytes were isolated with collagenase from livers of fed male Wistar rats (obtained from Mus Rattus, Brunnthal, FRG) by a recirculating in situ perfusion technique as previously described [26] . Cells were suspended in M 199 medium, containing 5 mmol/1 glucose, supplemented with dexamethasone (0.1 gmol/l), insulin (1 nmol/1) and 0.2% (weight/volume, w/v) BSA and cultured on 35 or 60 mm Falcon plastic dishes. For the first 3 h of culture, the medium was also supplemented with 4% (v/v) fetal calf serum. After 3 h the medium was replaced by serum-free medium. The medium was changed again at 24 h and 48 h of culture. The gas atmosphere contained 5% (v/v) CO2, 20% 0 2 and 75% N2.
Binding studies
Cells were cultured for 48 h. After washing the cells with M 199 medium, binding studies of l~sI-insulin and 125I-IGF-II were performed according to the method of Fleig et al.
[27] at 37~ and 4~ respectively. Briefly, cells were pre-incubated in serum-free M 199 medium supplemented with 2 retool/1 lactate and 0.1 gmol/1 dexamethasone for 1 h followed by the addition of 125I-insulin or 125I-IGF-II (-0.05 gCi/dish, hormone concentration 10-20 pmol/1) with or without various concentrations of unlabelled insulin or IGF-II. Cells were incubated with l~I-insulin for I h at 37~ and for 6 h at 4~ IGF-II binding was assessed after 6 h incubations at 4~ Incubations were terminated by aspirating the medium and rapidly washing the
Glycogen synthesis
Cells were cultured for 48 h in M 199 medium in the presence of insulin (0.1 nmol/1) and dexamethasone (0.1 gmol/1). After washing, hepatocytes were pre-incubated in the absence of insulin for 90 min, medium was changed and supplemented with 2 mmol/1 lactate and [14C]glucose (-0.8 gCi/dish) followed after 30 min by the addition of IGF-II or insulin. Incubations were terminated after 2 h by aspirating the medium and washing the cells with ice-cold phosphate buffered saline. Cells were kept in liquid nitrogen until analysis for radioactivity incorporated into glycogen. Glycogen was analysed using KOH and ethanol extraction [27] . Glycogen synthesis was linear for 3 h.
Arninoisobutyric acid (AIB) transport
After 48 h of culture cells were washed three times with M 199 medium, incubated for 120 rain in the presence of IGF-II or insulin followed by the addition of [3H]aminoisobutyric acid (AIB 8 gmol/1, -0.8 gCi/dish) and incubated for an additional 25 rain. After aspirating the medium and extensive washing with ice-cold phosphate buffered saline, cells were solubilized with NaOH (1 tool/l, 1 ml/dish) and AIB content determined as described [30] . AIB transport was linear for up to 50 min. After pre-incubation for 30 rain, zero time medium samples were taken, and the experiment started by the addition of insulin or IGF-II at the respective concentrations. The incubation was terminated after 3 h by aspiration of the medium. 
Enzyme induction
Cells were processed for glucokinase and pyruvate kinase assays using an Ultra-qSJrrax homogenizer (Janke and Kunkel, Staufen, FRG) in 50 mmol/1 HEPES, 100 mmol/l KC1, 5 mmol/1 MgC12, I retool/1 EDTA, 2.5 mmol/1 dithioerythritol and 10 mg/ml BSA at pH 7.5. Enzyme activities were determined as described [31] , with the addition of 0.1 mmol/1 fructose 1,6-bisphosphate in the pyruvate kinase assay. For the phosphoenolpyruvate carboxykinase assay, cells were homogenized in 50 mmol/1 Tris HC1, pH 8.1, containing 0.40 mmol/1 MnC12 and i mmol/1 dithioerythritol. Enzyme activity was measured according to Seubert and Huth [32] and DNA according to Oliver et al. [33] .
Internalization of [35 S]methionine-labelled arylsulphatase A
NH4C1 secretions of [35S]methionine-labelled baby hamster kidney
cells transfected with the cDNA of human arylsulphatase A were prepared as described [34] . Hepatocytes were incubated for 30 rain in M 199 medium, containing 20 mmol/1 HEPES pH 7.2 and 0.1% (w/v) BSA and for an additional 30 rain in the absence or presence of IGF-II/Man-6-P receptor antiserum (5 % (v/v)). Thereafter, the cells were incubated for 60 rain with labelled secretions in the absence or presence of receptor antiserum, Man-6-P (5 mmol/1) or IGF-II (100 nmol/1). Following washing, arylsulphatase A was immunoprecipitated from cell lysates as described [35] and visualized after SDS/PAGE (10% polyacrylamide) by fluorography.
Results
Binding to cultured hepatocytes
When cells were incubated with labelled IGF-II at 4~ about 25% of the total radioactivity was cell-associated with virtually no degradation observed of labelled ligand. Half-maximal displacement occurred at IGF-II concentrations of about 1 nmol/1 (Fig. 1 A) . Non-specific binding was below 15% of cell-associated radioactivity. Addition of insulin at concentrations of up to 10 gmol/1 did not result in displacement of labelled IGF-II (Fig. 1 A) . When cells were incubated with labelled insulin, about 10% of total radioactivity added was cell-associated. Both peptides displaced cell-associated insulin, however IGF-II concentrations approximately 50 times higher were required for half-maximal displacement (about 0.2 nmol/1 for insulin and about 10 nmol/l for IGF-II; Fig. 1 B) .
Immunoprecipitation of lGF-II/Man-6-P receptor and cross-linking of l251-IGF-H to hepatocytes
The specificity of the antiserum directed against the human IGF-II/Man-6-P receptor was assayed by immunoprecipitation of metabolically-labelled hepatocytes and hepatocytes cross-linked to 125I-IGF-II. Immunoprecipitation of [35S]methionine-labelled hepatocytes with the antiserum followed by SDS-PAGE under reducing conditions identified a protein band of about 300 kDa (Fig. 2,  lane 1) . This protein co-migrated with a hepatocyte pro- (Fig. 2, lane 3) and with the purified human IGF-II/Man-6-P receptor cross-linked to ~2sI-IGF-II (not shown). Remarkable labelling of smaller proteins was not observed. The major polypeptide to which ~25I-IGF-II was cross-linked could be immunoprecipitated by the antiserum against the human IGF-II/ Man-6-P receptor (Fig. 2, lane 4) . Complete competition for ~25I-IGF-II binding occurred in the presence of an excess of unlabelled IGF-II (Fig. 2, lane 2) .
Stimulation of glycogen synthesis
IGF-II and insulin stimulated glycogen synthesis from [14C]glucose about three-fold (Fig.3A) . Half-maximal stimulation occurred at insulin concentrations of about 0.15nmol/1 and at IGF-II concentrations of about 10 nmol/1 (Fig. 3 A) .
Stimulation of AIB transport
Transport of AIB was doubled by the addition of both peptides at maximally effective concentrations (Fig. 3 B) . Half-maximal responses were observed at concentrations of insulin of about 0.8 nmol/1 and of IGF-II of about 10 nmol/1 (Fig. 3 B) . (Fig. 3 C) . Compared to insulin an identical maximal response was not observed at the IGF-II concentrations tested.
Inhibition of basal and glucagon-activated glycogenolysis
Spontaneous release of [14C]glucose from labelled glycogen was reduced to approximately 10% (Fig. 4 A) and glucagon-activated release was suppressed completely by IGF-II and insulin (Fig.4B) . Half-maximally effective concentrations were at least 50 times higher for IGF-II than for insulin. 
Induction of glucokinase and pyruvate kinase
Inhibition of gIucagon-dependent induction of phosphoenolpyruvate carboxykinase
Glucagon at a concentration of 0.1 nmol/1 increased the enzyme's activity about four-fold after a 4 h incubation. This increase was reduced by IGF-II and insulin in a concentration-dependent manner with half-maximally effective concentrations of about 2 nmol/1 and 0.2 nmol/1 respectively (Fig. 5) .
Inhibition of endocytosis of arylsulphatase A by antibodies against the IGF-II/Man-6-P receptor
Previous work suggested that treatment of human fibroblasts with antibodies against the human IGF-II/Man-6-P receptor interferred with receptor functions in intracellular sorting and endocytosis of lysosomal enzymes [38] . Similarly, incubation of hepatocytes with 1 and 5% antiserum against the receptor inhibited the endocytosis of the Man-6-P-containing enzyme arylsulphatase A by about 70 and 84%, respectively (Fig. 6, lane 3, 4) . Complete inhibition was observed in the presence of Man-6-P (Fig. 6 , lane 2). In the presence of 100 nmol/1 IGF-II the internalization of arylsulphatase A was decreased by 54% (Fig. 6 , lane 5). Treatment of hepatocytes for 30 min with IGF-II (100 nmol/1) prior to the addition of arylsulphatase A reduced the endocytosis by about 90% compared to control cells (not shown).
Effect of IGF-II/Man-6-P receptor antiserum on IGF-II binding and on IGF-II-stimulated glycogen synthesis
When cells were incubated in the presence of 5% antiserum against the IGF-II/Man-6-P receptor the binding of ~25I-IGF-II was inhibited by about 50% (Fig.7) . At the same antiserum concentration stimulation of glycogen synthesis by insulin (5 nmol/1) and IGF-II (0.1 gmol/1) was unaffected (Fig. 7) . The present work demonstrates that cultured hepatocytes from adult rats expressed the IGF-II/Man-6-P receptor at the cell surface. The data from cross-linking experiments with 125I-IGF-II at tracer concentrations followed by immunoprecipitation with an antiserum raised against the human IGF-II/Man-6-P receptor revealed a single protein of an apparent molecular weight of about 300 kDa. Binding of ]25I-IGF-II to this protein was sensitive to unlabelled IGF-II and Man-6-P. Furthermore, the affinity of IGF-II to the receptor, with half-maximal displacement of 125I-IGF-II occurring at IGF-II concentrations of about i nmol/1, was similar to data obtained previously with the purified human IGF-II/Man-6-P receptor and with Chinese hamster ovary cells transfected with IGF-II/Man-6-P receptor cDNA [9, 39] . Apparently insulin was unable to interfere with the IGF-II/Man-6-P receptor of rat hepatocytes, this observation being consistent with results from previous studies using rat liver plasma membranes and other cells [8] . The IGF-II/Man-6-P receptor-mediated endocytosis of the lysosomal enzyme arylsulphatase A could be suppressed in the presence of Man-6-P and IGF-II. Similar observations have been made in rat BRL 3A2 liver and C6 glial cells [40] . For these latter cells it was proposed that IGF-II decreased the affinity of the receptor for Man-6-P-containing ligands [29] . Because of limited amounts of labelled arylsulphatase A in the present investigation it was not possible to evaluate IGF-IIdependent changes in receptor affinity for arylsulphatase A. Alternatively, receptor occupation with IGF-II could interfere with the Man-6-P binding site thus preventing binding and internalization of arylsulphatase A. Fig.7 . Effect of insulin-like growth factor II/mannose 6-phosphate (IGF-II/Man-6-P) receptor antiserum on IGF-II binding and on IGF-II-stimulated glycogen synthesis in cultured hepatocytes. Cells were incubated (upper part) with lzsI-IGF-II as described in the legend to Figure 1 in the presence or absence of unlabelled IGF-II, insulin or an IGF-II/Man-6-P receptor antiserum (cMGF If-R). Glycogen synthesis (lower part) was measured as described in the legend to Figure 3 in the absence or presence of c~-IGF II-R. Data are mean + SD of a typical experiment each performed in triplicate strated cellular responses to IGF-II through an interaction with hepatic insulin receptors. Additionally, previous work using adult rat hepatocytes in primary cultures suggested that IGF-I may also exert metabolic actions through insulin receptors [41] . Since antibodies against rat hepatic insulin receptors capable of blocking insulin-dependent actions have not yet been obtained, the receptor specificity could not be ascertained. It is of interest however, that hepatocytes from adult rats express hardly any IGF-I receptors [23] , thus supporting the present suggestion that IGF-II metabolic actions might be mediated through insulin receptors. This conclusion is in contrast to data from previous studies particularly that observing a stimulatory action of IGF-II on glycogen synthesis [13] . Using HEP-G2 cells and specific antibodies against individual receptors for insulin, for IGF-I and IGF-II, Hari et al. suggested a signalling mechanism via the IGF-II/Man-6-P receptor for the stimulation of glycogen synthesis. Interestingly, antibodies to the IGF-II/Man-6-P receptor demonstrated a stimulatory action per se. An explanation for this discrepancy with respect to the present observations is not obvious. However, differences in hormonal re-H. Hartmann et al.: Metabolic effects of IGF-II on rat hepatocytes sponses between rat hepatocytes and hepatoma cell lines have been previously reported [42] . Several other studies support the present suggestion that cellular signalling for metabolic actions is, at least in adult rat hepatocytes, unlikely to involve the IGF-II/Man-6-P receptor [8, [19] [20] [21] [22] . Finally, using IGF-II analogues with markedly reduced affinity to both the IGF-I and insulin receptor it has been demonstrated that "somatomedin-like" actions of IGF-II, e.g. stimulation of DNA synthesis, were not mediated through the IGF-II/Man-6-P receptor [43, 44] . The physiological role of the cell surface IGF-II/Man-6-P receptor in adulthood appears to be the binding and degradation of IGF-II as well as endocytosis of Man-6-Pcontaining ligands (lysosomal enzymes) thereby modulating their extracellular concentrations.
